Laura Mezquita

Epidemiology · 2010–2019

A researcher in the Science corpus: 6 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Laura Mezquita trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Sherry H. Stewart

Papers from Laura Mezquita's perspective

Ordered by how strongly the researchers Laura Mezquita trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Big-Five personality domains predict drinking motives
  2. Checkpoint Inhibitors in Metastatic EGFR‐Mutated Non–Small Cell Lung Cancer—A Meta‐Analysis (Journal of Thoracic Oncology)
  3. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer (New England Journal of Medicine)
  4. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics (The Lancet Oncology)
  5. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer (JAMA Oncology)
  6. Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC (New England Journal of Medicine)
  7. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. (The Lancet)
  8. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma (Cancer Discovery)
  9. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer (NSCLC): A Retrospective Analysis (Clinical Cancer Research)
  10. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. (Journal of Clinical Oncology)

Their papers